Accuray Inc. and Lancaster General Health announced that the first commercially available InCise multileaf collimator (MLC) for the CyberKnife M6 System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system's treatment efficiency and extend its unique capabilities to a broader range of patient cases.

smoking, lung cancer, CT screening, guidelines

A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don’t qualify for low-dose computed tomography (CT) scans, according to a group of Mayo Clinic researchers. Their research appears in the Feb. 24 issue of JAMA, the journal of the American Medical Association.

Americans are ready and willing to leverage health apps and wearable devices to improve their personal health, according to the findings released from the fifth annual Makovsky/Kelton "Pulse of Online Health" Survey.

Spellman High Voltage Electronics Corp. announced that it has signed an agreement with Power Valley Technologies of Beijing, China, to purchase the commercial assets and technologies of their power conversion group.

Together with physicians, other research groups, and industry partners, Fraunhofer MEVIS is developing software to optimize radiation therapy. The fifth clinical workshop to evaluate this software took place in Bremen on Feb. 5-6.

Researchers at the University of California Los Angeles (UCLA) have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

New research from Johns Hopkins School of Medicine reveals a high value for scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of The Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.

Pie Medical Imaging BV announced that it received 510(k) clearance from the U.S. Food and Drug Administration for its CAAS A-Valve product including the quantitative Regurgitation Analysis (qRA) workflow. The qRA workflow is the first 510(k) cleared image analysis technology to determine aortic regurgitation based on X-ray angiography.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now